Vinhas J, Assis P, Oliveira C, Crespo F, Prata M M
Serviços de Nefrologia do Hospital de Santa Cruz, Carnaxide.
Acta Med Port. 1991 Jan-Feb;4(1):9-12.
End-stage chronic renal failure (CRF) is often associated with platelet' disfunction and therefore with impaired hemostasis. Several investigators have reported that rHu Epo, used in the treatment of CRF anaemia, is able to activate a broad spectrum of hematopoietic stem cells, and therefore is able to increase the number of platelets and to induce correction of platelet disfunction. In order to investigate hemostasis changes associated with rHu Epo we studied 8 dialysis patients before and 12 weeks after rHu Epo. RHu Epo did not induce any change in the number of platelets (187710 +/- 52690 vs 204430 +/- 68710; p = NS), but seemed to improve its function (MI% of aggregation with ADP: 46.3 +/- 4.4% vs 49.1 +/- 5.3%; p less than 0.05). There was an improvement in PT (79.0 +/- 3.0% vs 87.5 +/- 8.9%; p less than 0.02) and aPTT (33.3 +/- 5.9" vs 29.3 +/- 2.1"; p less than 0.05) suggesting an improvement in platelet coagulant activities. These preliminary results indicate that rHu Epo does not increase the number of platelets but can induce a correction of platelet disfunction.
终末期慢性肾衰竭（CRF）常伴有血小板功能障碍，进而导致止血功能受损。一些研究者报告称，用于治疗CRF贫血的重组人促红细胞生成素（rHu Epo）能够激活广泛的造血干细胞，因此能够增加血小板数量并诱导血小板功能障碍的纠正。为了研究与rHu Epo相关的止血变化，我们对8例透析患者在使用rHu Epo之前和之后12周进行了研究。rHu Epo并未引起血小板数量的任何变化（187710±52690对204430±68710；p=无显著性差异），但似乎改善了其功能（ADP诱导的聚集MI%：46.3±4.4%对49.1±5.3%；p<0.05）。凝血酶原时间（PT）有所改善（79.0±3.0%对87.5±8.9%；p<0.02），活化部分凝血活酶时间（aPTT）也有所改善（33.3±5.9秒对29.3±2.1秒；p<0.05），提示血小板凝血活性有所改善。这些初步结果表明，rHu Epo不会增加血小板数量，但可诱导血小板功能障碍的纠正。
